Canaccord Genuity analyst Edward Nash reiterated a Buy rating and $38.00 price target on Corcept Therapeutics (NASDAQ: CORT).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE